Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics

Published on: July 16, 2018

Tumor detection by imaging proteolytic activity.

Molly R Darragh¹, Eric L Schneider, Jianlong Lou

¹Graduate Group in Biophysics, Department of Pharmaceutical Chemistry, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California 94158, USA.

Cancer Research

|February 11, 2010

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A belt-buckle checkpoint regulates the onset of botulinum neurotoxin intoxication.

Nature communications·2026

Same author

A Prodrug Strategy to Conditionally Trap Therapeutic Payloads for Improved Tumor Retention.

ACS central science·2026

Same author

Structural Basis of Serine Protease Inhibition by Antibodies from Biased Fab Phage-Display Libraries.

bioRxiv : the preprint server for biology·2026

Same author

Structure-guided design of a targeted autoantibody degrader for neurologic disease.

bioRxiv : the preprint server for biology·2026

Same author

Coupling high-throughput protease enzymology with viral replication reveals biochemical constraints of viral fitness.

bioRxiv : the preprint server for biology·2026

Same author

Pathophysiological and therapeutic implications of C-type natriuretic peptide/cyclic GMP signaling in pulmonary fibrosis.

JCI insight·2026

Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026

Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026

Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026

Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026

Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026

Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026

See all related articles

Researchers developed a noninvasive antibody-based method to visualize epithelial cancers by targeting membrane-type serine protease-1 (MT-SP1) activity. This approach successfully detected MT-SP1-positive tumors in vivo, offering a new tool for cancer imaging.

Area of Science:

Biochemistry
Molecular Biology
Oncology

Background:

Membrane-type serine protease-1 (MT-SP1), or matriptase, is a cell surface protease frequently upregulated in epithelial cancers.
Dysregulation of MT-SP1 and its inhibitor hepatocyte growth factor activator inhibitor-1 (HAI-1) increases proteolytic activity, presenting a potential target for cancer imaging.

Purpose of the Study:

To investigate if MT-SP1 activity can be targeted in vivo for tumor detection and differentiation between malignant and normal tissues.
To validate the use of MT-SP1 antibodies for noninvasive imaging of epithelial cancers.

Main Methods:

Utilized proteolytic activity assays on human cancer cell lines with varying MT-SP1 expression levels.
Employed fluorescence microscopy to confirm cell surface localization of MT-SP1 antibodies.

More Related Videos

Detection of Protease Activity by Fluorescent Peptide Zymography

Detection of Protease Activity by Fluorescent Peptide Zymography

Published on: January 20, 2019

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Related Experiment Videos

Last Updated: Jun 16, 2026

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics

Nanosensors to Detect Protease Activity In Vivo for Noninvasive Diagnostics

Published on: July 16, 2018

Detection of Protease Activity by Fluorescent Peptide Zymography

Detection of Protease Activity by Fluorescent Peptide Zymography

Published on: January 20, 2019

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Administered fluorescently labeled MT-SP1 antibodies to mice bearing MT-SP1-positive and MT-SP1-negative tumors to assess in vivo targeting.

Main Results:

MT-SP1 antibodies inhibited MT-SP1 activity on cancer cells in vitro and bound to the cell surface.
MT-SP1-positive tumors showed significant antibody localization and visualization in vivo.
MT-SP1-negative tumors did not exhibit antibody localization, confirming target specificity.

Conclusions:

MT-SP1 activity serves as a viable biomarker for visualizing epithelial cancers.
Noninvasive antibody-based imaging targeting MT-SP1 activity is feasible for tumor detection.
This method holds promise for differentiating malignant from normal tissues in cancer diagnostics.